Abstract
Objectives: This paper aimed to critically review the current literature concerning the possible association between cannabis use and suicidal behavior in patients with psychosis and in non-psychotic samples.
Methods: We performed a detailed Pubmed/Medline, Scopus, PsycLit, and PsycInfo search to identify all papers and book chapters focusing on the association between cannabis use, and suicidal behavior during the period between 1980 and 2011.
Results: Most, but not all studies reported an association between suicidal behavior and cannabis use both in psychotic and non-psychotic samples. However, there were also some studies suggesting a weak (not direct) association between these two phenomena. Overall, those who attempt or complete suicide are characterized by additional risk factors such as mood disorders, stressful life events, interpersonal problems, poor social support, lonely lives, and feelings of hopelessness.
Limitations: It was not possible to perform a meta-analysis due to the high heterogeneity of individual data.
Conclusions: Cannabis use was a relevant risk factor associated with both suicidal attempts and behaviors in psychotic and non-psychotic samples. Preventive programs should be directed on reducing cannabis use, particularly in psychotic subjects. Evidence suggests that targeted suicide prevention programs can be also developed in specific at-risk subgroups such as those at genetic or clinical high risk of psychosis.
Keywords: Cannabis use, suicidal behavior, psychosis, youths, prevention.
Current Pharmaceutical Design
Title:Can Cannabis Increase the Suicide Risk in Psychosis? A Critical Review
Volume: 18 Issue: 32
Author(s): Gianluca Serafini, Maurizio Pompili, Marco Innamorati, Zoltan Rihmer, Leo Sher and Paolo Girardi
Affiliation:
Keywords: Cannabis use, suicidal behavior, psychosis, youths, prevention.
Abstract: Objectives: This paper aimed to critically review the current literature concerning the possible association between cannabis use and suicidal behavior in patients with psychosis and in non-psychotic samples.
Methods: We performed a detailed Pubmed/Medline, Scopus, PsycLit, and PsycInfo search to identify all papers and book chapters focusing on the association between cannabis use, and suicidal behavior during the period between 1980 and 2011.
Results: Most, but not all studies reported an association between suicidal behavior and cannabis use both in psychotic and non-psychotic samples. However, there were also some studies suggesting a weak (not direct) association between these two phenomena. Overall, those who attempt or complete suicide are characterized by additional risk factors such as mood disorders, stressful life events, interpersonal problems, poor social support, lonely lives, and feelings of hopelessness.
Limitations: It was not possible to perform a meta-analysis due to the high heterogeneity of individual data.
Conclusions: Cannabis use was a relevant risk factor associated with both suicidal attempts and behaviors in psychotic and non-psychotic samples. Preventive programs should be directed on reducing cannabis use, particularly in psychotic subjects. Evidence suggests that targeted suicide prevention programs can be also developed in specific at-risk subgroups such as those at genetic or clinical high risk of psychosis.
Export Options
About this article
Cite this article as:
Serafini Gianluca, Pompili Maurizio, Innamorati Marco, Rihmer Zoltan, Sher Leo and Girardi Paolo, Can Cannabis Increase the Suicide Risk in Psychosis? A Critical Review, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884663
DOI https://dx.doi.org/10.2174/138161212802884663 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Promoted Zirconia Solid Acid Catalysts for Organic Synthesis
Current Organic Chemistry Involvement of the Apoer2 and Lrp1 receptors in mediating the pathological effects of ApoE4 in vivo
Current Alzheimer Research Coping Responses in Obsessive-Compulsive Disorder: Avoidance, Treatment, and Lifestyle Factors
Current Psychiatry Reviews Acute Effects of Oral Tofisopam on Plasma Concentration and Urinary Excretion of Uric Acid and Oxypurinol “Preliminary Communication”
Current Clinical Pharmacology Pharmacological Treatment of Cognitive Symptoms in Alzheimer's Disease
Current Psychopharmacology New Approaches to Develop Drug Treatment for Alzheimer’s Disease: Targeting Calcium Dysregulation
Current Alzheimer Research Depression and Anxiety During Pregnancy: Clinical Aspects
Current Psychiatry Reviews Vascular Toxicity of Chemotherapeutic Agents
Current Vascular Pharmacology Mouse Models of Autoimmune Diseases: Immune Thrombocytopenia
Current Pharmaceutical Design Understanding Unmet Needs in the Older Acute Myeloid Leukemia (AML) Patient
Current Cancer Therapy Reviews Calculation of Young's Modulus Value by Means of AFM
Recent Patents on Nanotechnology The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Allocentric to Egocentric Spatial Switching: Impairment in aMCI and Alzheimer's Disease Patients?
Current Alzheimer Research Identifying Keystone Species in the Microbial Community Based on Cross- Sectional Data
Current Gene Therapy Immunotherapy and Targeted Therapy Combinations in Renal Cancer
Current Clinical Pharmacology Spectral Methods of Characterizing the Conformational Changes of Glycated Goat Liver Cystatin
Current Proteomics Reconstruction of the Network of Experimentally Validated AMP-Drug Combinations Against Pseudomonas aeruginosa Infections
Current Bioinformatics Cytochromes P450 in the Bioactivation of Chemicals
Current Topics in Medicinal Chemistry Design and Analysis of a Dual-Mode MEMS Micromirror
Micro and Nanosystems Recent Advances in Perioperative Anesthetic Management Update in the Perioperative Support of Patients with Septic Shock and the Effect on Outcomes
Current Pharmaceutical Design